- Research article
- Open Access
- Open Peer Review
Is new drug prescribing in primary care specialist induced?
© Florentinus et al; licensee BioMed Central Ltd. 2009
- Received: 25 October 2007
- Accepted: 11 January 2009
- Published: 11 January 2009
Medical specialists are often seen as the first prescribers of new drugs. However, the extent to which specialists influence new drug prescribing in primary care is largely unknown.
This study estimates the influence of medical specialists on new drug prescribing in primary care shortly after market introduction. The influence of medical specialists on prescribing of five new drugs was measured in a cohort of 103 GPs, working in 59 practices, over the period 1999 until 2003. The influence of medical specialists on new drug prescribing in primary care was assessed using three outcome measures. Firstly, the proportion of patients receiving their first prescription for a new or reference drug from a specialist. Secondly, the proportion of GPs prescribing new drugs before any specialist prescribes to their patients. Thirdly, we compared the time until the GP's first own prescribing between GPs who waited for prescriptions from specialists and those who did not.
The influence of specialists showed considerable differences among the new drugs studied. The proportion of patients receiving their first prescription from a specialist was greatest for the combination salmeterol/fluticasone (60.2%), and lowest for rofecoxib (23.0%). The proportion of GPs prescribing new drugs before waiting for prescriptions from medical specialists ranged from 21.1% in the case of esomeprazole to 32.9% for rofecoxib. Prescribing new drugs by specialists did not shorten the GP's own time to prescribing.
This study shows that the influence of medical specialists is clearly visible for all new drugs and often greater than for the existing older drugs, but the rapid uptake of new drugs in primary care does not seem specialist induced in all cases. GPs are responsible for a substantial amount of all early prescriptions for new drugs and for a subpopulation specialist endorsement is not a requisite to initiate in new drug prescribing. This contradicts with the idea that the diffusion of newly marketed drugs always follows a two-step model, with medical specialists as the innovators and GPs as the followers.
- Primary Care
- Medical Specialist
Prescribing of newly marketed drugs is not uniformly distributed among physicians. A minority of physicians is responsible for the majority of all early prescriptions for new drugs shortly after market introduction [1–3]. The interface between primary and specialist care is an important factor in the mixture of drugs prescribed by general practitioners (GPs) . In healthcare systems where GPs function as gatekeepers for accessing specialist care, like in the UK and the Netherlands, referral of patients and repeat prescribing of specialist-initiated prescription are important mechanisms through which specialists influence GP prescribing [5, 6].
Two studies found GPs' prescribing behaviour to be a derivative of specialist prescribing by showing that 60–66% of all drugs prescribed by GPs were initiated by medical specialists [7, 8]. However, these studies did not differentiate between new and old drugs. Tamblyn et al. found no indications that repeat prescribing of specialist prescriptions influenced the GP's prescribing of new drugs . In addition, Robertson et al. noted that prescriptions for more recently introduced drugs were not more likely to have been specialist initiated than older drugs . So despite the acknowledged impact that specialists have on the prescribing of existing drugs by GPs, little data are available when it comes newly marketed drugs.
Better understanding of the interplay between primary and specialist care, and thereby the mechanisms by which new drug diffuse into medical practice, contribute to the discussion on ensuring patient safety and a sustainable cost-containment in health care [10, 11]. Therefore, the aim of this study was to estimate the influence of medical specialists on new drug prescribing in primary care shortly after market introduction. We were interested in three questions. Firstly, are newly marketed drugs in primary care mainly prescribed by medical specialists during the early post-marketing period? Secondly, how many GPs start prescribing new drugs before medical specialists do so? Thirdly, does specialist prescribing shorten the GP's time to adoption?
In this study we used dispensing data from patients of 103 GPs who participated in the second Dutch national survey of general care (DNSGP-2), conducted by NIVEL (Netherlands Institute for Health Services Research) in 2001 [12, 13]. The 103 GPs worked in 59 non-dispensing practices in all 12 provinces of the Netherlands. Dispensing data were collected by the network of the Foundation for Pharmaceutical Statistics (SFK) and covered the period 1999 until 2003 . Because virtually all patients in the Netherlands designate a single pharmacy to fill prescriptions from both GPs and medical specialists, dispensing data provide an almost complete account of drug exposure in time .
Characteristics of the five newly marketed drugs included in the study
New drug (Brand name)
Long acting β2-agonist and ICS
NSAIDs excl. low-dose aspirin
Proton pomp inhibitors
Ipratropiumbromide containing products
HMG CoA reductase inhibitors
With the introduction of a new drug, physicians can either treat a patient with the tried and proven existing drug (if available) or the newly introduced drug. As reference drugs for the selected study case drugs we used all long-acting beta-2 antagonists and ICS for the combination salmeterol/fluticasone, all ipratropium bromide containing products for tiotropium, all non-steroidal anti-inflammatory drugs (NSAIDs) (excl. low-dose aspirin) for rofecoxib, all proton pump inhibitors for esomeprazole and all HMG-CoA reductase inhibitors for rosuvastatin. All five new drugs showed rapid market introduction and were listed within one year after market introduction in the top 10 drugs associated with the fastest growing expenditures in the Netherlands . All drugs were fully reimbursed by all health insurance companies and could be prescribed without limitation by both GPs as medical specialists.
For this study we included patients starting on a new or a reference drug during the first six months after market introduction. We included both new starters and switchers. The date of the patient's first prescription for either the new or reference drug was termed the index date. Starting was defined as receiving a prescription for a new or reference drug and no prescription for that same drug during the six months before the index date. Patients in whom dispensing follow-up of less than six months was present were excluded. Market introduction was defined as the date of the first prescription for the new drug in the database.
Main outcome measurements
We recorded the type of physician (GP or medical specialist) using the patient's prescription for a new or reference drug on the index date. To answer the first research question, we calculated per new drug the proportion of patients receiving their first prescription for a new drug from a medical specialist out of the total number of patients receiving the drug from both GPs and medical specialists. The same proportion was calculated for the reference groups to calculate a relative rate. To answer the second research question of how many GPs start prescribing new drugs before waiting for any prescriptions of medical specialists, we calculated the proportion of GPs that started prescribing the new drug before any of their patients received the drug from a medical specialist. To answer the third research question we calculated for each GP the time between market introduction and the date on which the GP prescribed the new drug for the fist time to a patient who never used the drug before. We compared the time to prescribing between GPs that initiate therapy before one of their patients received the drug from a medical specialist and GPs that waited for specialist to prescribe first before prescribing themselves.
In total 1,687 patients received one of the five new drugs during the first six months after market introduction. Most patients received rofecoxib (N = 596), followed by tiotropium (N = 556), rosuvastatin (N = 212), the combination salmeterol/fluticasone (N = 171) and esomeprazole (N = 152). The average age was 61.7 years (SD 15.3 years) and 57.2% was female. Overall 16,797 patients received a drug from the reference groups (mean age 51.9 years (SD 18.7); 58.8% female). Complete dispensing data were available for 80 GPs for the combination salmeterol/fluticasone. The number of included GPs for rofecoxib was 85, 90 for esomeprazole, 98 for tiotropium, and 94 for rosuvastatin.
New drug prescribing on patient level.
New drug N (%)
Reference drug N (%)
Relative Rate (95% CI)
New drug prescribing on GP level.
Total number of GP
GPs with at least one patient in their practice receiving new drug
GPs initiating therapy with new drugs
GPs initiating therapy without waiting for a specialist prescription
The influence of medical specialist prescribing on the average number of days (SD) to the GP's first prescription for a new drug in the first six months after market introduction.
GPs starting therapy before repeating a specialist prescription
GPs starting therapy after repeating a specialist prescription
Mean days (SD)
Mean days (SD)
The primary objective of this study was to estimate the influence of medical specialists on new drug prescribing in primary care shortly after market introduction. This study shows that the influence of medical specialists is clearly visible for all new drugs and often greater than for the existing older drugs, but the rapid uptake of new drugs in primary care does not seem specialist induced by definition and very much drug dependent. A substantial proportion of GPs that prescribe new drugs do so without awaiting specialist prescribing.
The main advantage of this study was the possibility to identify within individual GP practices patients that received a new drug from a specialist and those receiving a prescription from their own GP. This clear distinction enabled us to estimate the influence of medical specialists on new drug prescribing in primary care. In addition, we measured the specialists' influence on new drug prescribing shortly after a new drug's market introduction in comparison to their influence on the prescribing of drugs from the same therapeutic category already present on the market.
Research on diffusion of innovations postulated a two-step model by which innovations are adopted by a population with innovators as the individuals who adopt first, followed by others copying their behaviour [16, 17]. Because GPs regard medical specialists as the opinion leaders in specific medical area, they often mention specialists as the early prescribers of new drugs [18, 19]. It is therefore reasonable to assume that the diffusion of new drugs also follows this two-steps model with medical specialists as innovators and GPs as followers. However, our data show that this is not the case for all new drugs. Even in the early post-marketing period in which new drug prescribing by specialists should be predominant, GP prescribing outweighed specialist prescribing in three out of the five new drugs. Moreover, we noted that specialist endorsement was not a requisite for a subpopulation of GPs. Especially rofecoxib, and in a lesser extent rosuvastatin and esomeprazole, was adopted by the majority of GPs and 32.9% adopted before ever having seen a specialist prescription for rofecoxib. Although the influence of specialists is clearly visible, GPs are innovators too.
The level of specialist prescribing differs per new drug. Especially for rosuvastatin, esomeprazole, and rofecoxib, GP were in most cases the first prescribers. On the other hand, tiotropium and the combination salmeterol/fluticasone were mostly initiated by specialists. This is in line with other studies [8, 9, 20, 21]. Robertson et al. noted in a study among 88 Australian GPs that the proportion of specialist-initiated prescriptions ranged from 8% to 85% for different drug classes . The smaller influence of medical specialists for rosuvastatin, esomeprazole, and rofecoxib may partly be explained by extensive marketing and the relative low perceived risk associated with prescribing of these drugs [22–24]. Extensive marketing campaigns may have resulted in less reluctance of GPs to adopt the new drugs fast. Moreover, rofecoxib, esomeprazole, and rosuvastatin are clear examples of new drugs showing rapid uptake in primary care that is not specialist induced.
We found that for four new drugs the likelihood of receiving a new drug from a medical specialist was significantly higher than receiving a reference drug. Only for rosuvastatin, no difference was observed. The difference between drugs may partly be explained by differences between patients receiving new drugs and those receiving reference drugs. In general, medical specialists treat a different patient mix primarily composed of more severely ill patients that may be more likely to benefit from new drugs [25, 26]. In previous studies on new drug prescribing we have identified channelling of new marketed drugs in high-risk patients and those with poor a response existing therapies [25–27].
Based on the classical model of innovation, specialist prescribing could serve as a catalyst for GPs to try out the new drugs themselves. Rapid prescribing of newly marketed drugs by specialists could convince GPs through a learning-by-demonstration effect to adopt too. However, this is not confirmed by our data showing that the time to first prescription was not shorter for GPs who awaited specialist prescribing compared those prescribing before any of their patients received the drug from a medical specialist. The absence of any differences may partly be explained by seemingly great willingness among GPs to prescribe these newly marketed drugs.
The findings in this study need to be interpreted in light of its limitations. Firstly, the results are based on five new drugs and this should be taken into account when generalising the results to all new drugs. Our dispensing data contained no information on the diagnosis that may have influenced the likelihood the patient may have referred to medicals. Furthermore, we used dispensing data as a proxy of physician prescribing. Patients do not fill all prescriptions they receive from their physician in a pharmacy. It is therefore possible that the dispensing data are conservative estimations of the real prescribing of physicians. However, we had no indications that the filling rate of patients was more selective for one of the five new drugs or differed between GPs and specialists. Hospital pharmacies that dispense medication to patients visiting the hospital is still limited in the Netherlands. It is therefore unlikely that we missed prescriptions of specialists to the patients of the study GPs.
This study shows that the influence of medical specialists is clearly visible for all new drugs and often greater than for older drugs, but the rapid uptake of new drugs in primary care does not seem specialist induced in all cases. GPs are responsible for a substantial amount of all early prescriptions for new drugs and for a subpopulation specialist endorsement is not a requisite to initiate in new drug prescribing. This contradicts with the idea that the diffusion of newly marketed drugs always follows a two-step model, with medical specialists as the innovators and GPs as the followers.
This study was supported by an unrestricted grant from the Royal Dutch Pharmaceutical Society (KNMP), The Hague, The Netherlands
- Inman W, Pearce G: Prescriber profile and post-marketing surveillance. Lancet. 1993, 342: 658-661. 10.1016/0140-6736(93)91763-C.View ArticlePubMedGoogle Scholar
- Tamblyn R, McLeod P, Hanley JA, Girard N, Hurley J: Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care. 2003, 41: 895-908. 10.1097/00005650-200308000-00004.View ArticlePubMedGoogle Scholar
- Leufkens HG, Urquhart J: Prescriber profile and postmarketing surveillance. Lancet. 1993, 342: 1178-10.1016/0140-6736(93)92163-N.View ArticlePubMedGoogle Scholar
- Pryce AJ, Heatlie HF, Chapman SR: Buccaling under the pressure: influence of secondary care establishments on the prescribing of glyceryl trinitrate buccal tablets in primary care. BMJ. 1996, 313: 1621-1624.View ArticlePubMedPubMed CentralGoogle Scholar
- Avery AJ, Rodgers S, Heron T, Crombie R, Whynes D, Pringle M, Baines D, Petchey R: A prescription for improvement? An observational study to identify how general practices vary in their growth in prescribing costs. BMJ. 2000, 321: 276-81. 10.1136/bmj.321.7256.276.View ArticlePubMedPubMed CentralGoogle Scholar
- Cochrane RA, Mandal AR, Ledger-Scott M, Walker R: Changes in drug treatment after discharge from hospital in geriatric patients. BMJ. 1992, 305: 694-6.View ArticlePubMedPubMed CentralGoogle Scholar
- de Vries CS, van Diepen NM, Tromp TF, de Jong-van den Berg LT: Auditing GPs' prescribing habits: cardiovascular prescribing frequently continues medication initiated by specialists. Eur J Clin Pharmacol. 1996, 50: 349-52. 10.1007/s002280050121.View ArticlePubMedGoogle Scholar
- Feely J, Chan R, McManus J, O'Shea B: The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics. 1999, 16: 175-81. 10.2165/00019053-199916020-00006.View ArticlePubMedGoogle Scholar
- Robertson J, Fryer JL, O'Connell DL, Sprogis A, Henry DA: The impact of specialists on prescribing by general practitioners. Med J Aust. 2001, 175: 407-11.PubMedGoogle Scholar
- Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ: The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem?. JAMA. 1999, 281: 1728-1734. 10.1001/jama.281.18.1728.View ArticlePubMedGoogle Scholar
- Wood AJJ: The Safety of New Medicines: The Importance of Asking the Right Questions. JAMA. 1999, 281: 1753-1754. 10.1001/jama.281.18.1753.View ArticlePubMedGoogle Scholar
- Westert GP, Schellevis FG, de Bakker DH, Groenewegen PP, Bensing JM, Zee van der J: Monitoring health inequalities through general practice: the Second Dutch National Survey of General Practice. Eur J Public Health. 2005, 15: 59-65. 10.1093/eurpub/cki116.View ArticlePubMedGoogle Scholar
- Cardol M, Groenewegen PP, de Bakker DH, Spreeuwenberg P, van Dijk L, Bosch van den W: Shared help seeking behaviour within families: a retrospective cohort study. BMJ. 2005, 330: 882-10.1136/bmj.38411.378229.E0.View ArticlePubMedPubMed CentralGoogle Scholar
- Tinke J, Griens A: Facts and Figures 2001. 2001, Foundation for Pharmaceutical Statistics: The Hague; The Netherlands, [http://www.sfk.nl]Google Scholar
- Herings RM, Bakker A, Stricker BH, Nap G: Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health. 1992, 46: 136-40. 10.1136/jech.46.2.136.View ArticlePubMedPubMed CentralGoogle Scholar
- Coleman JS, Katz E, Menzel H: Medical Innovation: A Diffusion Study. 1966, The Bobbs-Merril Company, Inc.: New YorkGoogle Scholar
- Rogers E: Diffusion of Innovations. 1995, New York: Free PressGoogle Scholar
- Jacoby A, Smith M, Eccles M: A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. Br J Gen Pract. 2003, 53: 120-5.PubMedPubMed CentralGoogle Scholar
- Jones MI, Greenfield M, Bradley CP: Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 2001, 323: 378-85. 10.1136/bmj.323.7309.378.View ArticlePubMedPubMed CentralGoogle Scholar
- Himmel W, Tabache M, Kochen MM: What happens to long-term medication when general practice patients are referred to hospital?. Eur J Clin Pharmacol. 1996, 50: 253-7. 10.1007/s002280050103.View ArticlePubMedGoogle Scholar
- Robertson J, Treloar CJ, Sprogis A, Henry DA: The influence of specialists on prescribing by GPs. A qualitative study. Aust Fam Physician. 2003, 32: 573-6.PubMedGoogle Scholar
- Burton B: AstraZeneca digs in over advertising criticisms. BMJ. 2004, 328: 1035a-10.1136/bmj.328.7447.1035-a.View ArticleGoogle Scholar
- Florentinus SR, Heerdink ER, Klungel OH, de Boer A: Should rosuvastatin be withdrawn from the market?. Lancet. 2004, 364: 1577-10.1016/S0140-6736(04)17301-7. author reply 1578–9.View ArticlePubMedGoogle Scholar
- Josefson D: FDA warns Merck over its promotion of rofecoxib. BMJ. 2001, 323: 767a-10.1136/bmj.323.7316.767.View ArticleGoogle Scholar
- Florentinus SR, Nielsen MW, van Dijk L, Leufkens HG, Hansen EH, Heerdink ER: Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib. Eur J Clin Pharmacol. 2005, 62: 157-159. 10.1007/s00228-005-0891-z.View ArticleGoogle Scholar
- Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG: The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiol Drug Saf. 2005, 14: 437-441. 10.1002/pds.1123.View ArticlePubMedGoogle Scholar
- Leufkens HG, Urquhart J, Stricker BH, Bakker A, Petri H: Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems. J Epidemiol Community Health. 1992, 46: 428-32. 10.1136/jech.46.4.428.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/9/6/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.